COR logo

CENCORA INC

CORNYSE
πŸ† #218 by market capEarnings Nov 3 Β· PostUS Equity
$97.25β–Ό $7.41 (βˆ’7.62%)
Simulated price
1hβ€”
24hβ–Ό 7.6%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$62.02B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+5.1%
Slowing
πŸ“ŠGross Margin
4.0%
Thin
πŸ’΅FCF Margin
1.9%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
42
Weak
No chart data available for COR.

Trading Snapshot

Day Range
$96.27 – $99.15
52-Week Range
$244.82 – $377.54
Volume
$3.20B
Avg Volume
$3.93B
Shares Outstanding
194.6M
Next Earnings
Sep 14, 2026

Fundamentals Snapshot

Annual Revenue
$321.33B
Last Q Revenue
$84.75B
P/E Ratio
23.6
P/S Ratio
0.2x
EPS (TTM)
$13.45
Dividend Yield
0.75%

Why Investors Own COR

  • βœ“High-growth profile β€” revenue up +16.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 15% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$321.33Bβ–² +19.9% YoY
Gross Margin (TTM)
26.2%β–² +3.7% YoY
Operating Income (TTM)
$71.34Bβ–² +19.9% YoY
Free Cash Flow (TTM)
$48.52Bβ–² +19.9% YoY

About CENCORA INC

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
42/100

Analyst Price Target

β“˜
Average Target
$93.53
β–Ό βˆ’3.8% Downside
High Target$110.94
Low Target$78.82
Based on 16 analysts

Latest News & Updates